Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection
PLOS Neglected Tropical Diseases · 2026
DOI: 10.1371/journal.pntd.0013597 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PLOS Neglected Tropical Diseases, 2026. Verfasst von Colin Forsyth und 14 weiteren Autor:innen. Beteiligte Einrichtung: Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Chagas Disease, Trypanosoma cruzi, Trypanocidal Agents, Drug Development. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bem-Te-Vi Diversidade, Nationale Postcode Loterij, Médecins Sans Frontières.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Infection with the protozoan Trypanosoma cruzi leads to Chagas disease, a neglected tropical disease with potentially serious complications. Infection commonly takes place in childhood which can lead, without timely diagnosis and accurate treatment, to severe cardiac events and early mortality. For many years there were no pediatric formulations. Currently, there are two very effective treatments. Nevertheless, new drugs and shorter treatments are desirable. Therefore, the aim of this report is to provide a target product profile (TPP) to guide the development of pediatric formulations of new drugs for the treatment of children with Chagas disease.
Methods
A review of the relevant literature, focusing on the therapeutic options available for pediatric Chagas disease, was undertaken prior to setting up a TPP working group of recognized leaders in the field. After several drafts, the TPP was established through a consensus agreement by the group. For each attribute, essential and ideal requirements were defined, which specified the required TPP performance and use characteristics.
Results
The TPP for the development of formulations of new drugs for treatment of children with T. cruzi infection includes 15 different attributes. The target population was defined as newborns to adolescents up to 18 years. The essential indication for the target product would cover acute/congenital and chronic T. cruzi infection; the ideal indication would include chronic indeterminate, congenital and/or acute vector-borne T. cruzi infection; people who are immunosuppressed, and pregnant and breastfeeding women. An age-appropriate drug formulation, acceptable palatability, dose, and ease of administration were considered to be particularly important for children.
Conclusions
The TPP provides guidance for essential and ideal characteristics of formulations of new drugs for the treatment of children with T. cruzi infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil.
- Servicio de Parasitologia and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP) CONICET, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina.
- Fundación Mundo Sano, Buenos Aires, Argentina.
- Plataforma de atención integral a los pacientes con enfermedad de Chagas, Tariia, Bolivia.
- Universidad Autónoma Juan Misael Saracho, Tarija, Bolivia.
- Federación Internacional de Asociaciones de Personas Afectadas por la Enfermedad de Chagas (FINDECHAGAS), Mexico.
ORCID-Profile: María-Jesús Pinazo
Förderung
- Bem-Te-Vi Diversidade
- Nationale Postcode Loterij
- Médecins Sans Frontières
- Dutch Ministry of Foreign Affairs
- Federal Ministry of Education and Research (BMBF), Germany
- Swiss Agency for Development and Cooperation
- Department for International Development, UK Government
Zitieren
APA
Forsyth, C., Garcia-Bournissen, F., Moscatelli, G., Moroni, S., Pereiro, A., Ortiz-Daza, L., Cuevas, E. H., Tinajeros, F., Marques, T., Marchiol, A., Herazo, R., Seu, S., Sancho, J., Altcheh, J., & Pinazo, M. J. (2026). Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013597
Vancouver
Forsyth C, Garcia-Bournissen F, Moscatelli G, Moroni S, Pereiro A, Ortiz-Daza L, et al. Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection. PLOS Neglected Tropical Diseases. 2026. doi:10.1371/journal.pntd.0013597
BibTeX
@article{Forsyth2026,
author = {Forsyth, Colin and Garcia-Bournissen, Facundo and Moscatelli, Guillermo and Moroni, Samanta and Pereiro, Ana and Ortiz-Daza, Lourdes and Cuevas, Elvira-Idalia Hernández and Tinajeros, Freddy and Marques, Tayná and Marchiol, Andrea and Herazo, Rafael and Seu, Sandra and Sancho, Javier and Altcheh, Jaime and Pinazo, María-Jesús},
title = {Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
doi = {10.1371/journal.pntd.0013597}
}
EUVIMED